Our Pipeline

AnHeart is currently developing three precision oncology assets at various clinical stages.

Taletrectinib/AB-106 – Phase 2
a next-generation ROS1 inhibitor

ROS1 fusion-positive non-small cell lung cancer (NSCLC)

AB-218 – Phase 2
a mIDH1 inhibitor

Lower grade glioma, cholangiocarcinoma and other tumors

AB-329 – Phase 1
an AXL inhibitor

Combination therapy with checkpoint inhibitors or chemotherapy in NSCLC and other solid tumors

We are also advancing a number of preclinical precision oncology programs.

Development pipeline graphic for AnHeart Therapeutics

Development pipeline graphic for AnHeart Therapeutics

1. AnHeart out-licensed commercial rights in greater China to Innovent Biologics and in Korea to NewG Lab
2. Daiichi Sankyo keeps development and commercial rights in Japan

Taletrectinib / AB-106 (ROS1 inhibitor)

Taletrectinib is a novel best-in-class next-generation brain-penetrant ROS1 inhibitor which has demonstrated excellent potency against crizotinib resistance in tumors and has shown very good intracranial antitumor activity and a strong safety profile in ROS1 fusion-positive NSCLC patients. 

Learn More

AB-218 (mIDH1 inhibitor)

AB-218 is a brain-penetrant mIDH1 inhibitor for multiple solid tumors with IDH1 mutations.

Learn More

AB-329 (AXL inhibitor)

AB-329 is a potent and selective AXL inhibitor that can potentially be used in combination with other therapies to overcome resistance in multiple solid tumors and hematological cancers.

Learn More